Vertex Pharmaceuticals Incorporated

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) resulting from allegations that Vertex Pharmaceuticals may have issued materially misleading business information to the investing public.

If you purchased Vertex Pharmaceuticals securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Vertex Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 2, 2022, before trading hours, Vertex Pharmaceuticals issued a press release providing an update on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. Specifically, the press release revealed that “the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product.”

On this news, Vertex Pharmaceuticals’ stock price fell $11.26 per share, or 4%, to close at $261.96 per share on May 2, 2022.

Follow us on:
Company Name: Vertex Pharmaceuticals Incorporated
Stock Symbol: VRTX
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top